Public domain

GCC Generic Drug Market Trends, Share, Size, Opportunity and Forecasts 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021
Pharmaceutical, Other Manufacturing, Health, Packaging, Infectious diseases, Logistics, Supply chain management, Transport, Manufacturing, Software, Pharmaceuticals policy, Computer programming, Pharmaceutical industry, Free software, Generic drug, Public domain, GNU Compiler Collection

The "GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The GCC generic drug market reached a value of US$ 3.94 Billion in 2020.
  • Looking forward, the publisher expects the GCC generic drug market to exhibit strong growth during the next five years.
  • How has the GCC generic drugs market performed so far and how will it perform in the coming years?

Global Generic Drugs Market Research Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 2, 2021
Health, Pharmaceutical, Pharmaceutical industry, Pharmaceuticals policy, Life sciences, Health sciences, Generic drug, Public domain, Health, Medication

The "Generic Drugs Market Research Report: By Type, Application, Route of Administration, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Generic Drugs Market Research Report: By Type, Application, Route of Administration, Distribution Channel - Global Industry Analysis and Demand Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This is to be a major factor to propel the global generic drugs market size to $786.0 billion by 2030 from $278.4 billion in 2019, at a 10.0% CAGR between 2020 and 2030.
  • Generic drugs, on the other hand, are cost-effective, at the same time contain the same active ingredients and have a similar effect as patented drugs.
  • In this regard, the generic drugs market is also being driven by the patent expiry of blockbuster medications.

Medicure Announces Resignation of Chief Financial Officer and Succession Plan

Retrieved on: 
Wednesday, April 28, 2021
Pharmaceutical industry, Pharmaceuticals policy, Life sciences, Generic drug, Public domain, Medication, Health, Economic taxonomy

The Company thanks James for his significant contributions and leadership.\nThe Company has initiated a search for a new Chief Financial Officer with the capabilities and qualifications to accelerate Medicure\'s growth and business strategy.

Key Points: 
  • The Company thanks James for his significant contributions and leadership.\nThe Company has initiated a search for a new Chief Financial Officer with the capabilities and qualifications to accelerate Medicure\'s growth and business strategy.
  • "\nMedicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • Marley is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers.
  • To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected] .For more information on Medicure please visit www.medicure.com .

United States Generic Drugs Market Report 2020-2026: Focus on CNS, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Anti-infective & Oncology - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021
Health, Pharmaceutical, Health sciences, Pharmaceutical industry, Life sciences, Health, Pharmaceuticals policy, Pharmacy, Generic drug, Public domain, Medication, Drug, Prescription drug prices in the United States, Generic pharmaceutical price decay

b'The "United States Generic Drugs Market By Segment (Generic, Branded), Therapeutic Application, Company Analysis & Forecast" report has been added to ResearchAndMarkets.com\'s offering.\nUnited States Generic Drugs Market will be US$ 239.5 Billion by 2026.\nGenerics are an off-patented drug that is pharmaceutical equivalents to branded medicines in term of administrative dosage, quality, effect, intended use and side effects.

Key Points: 
  • b'The "United States Generic Drugs Market By Segment (Generic, Branded), Therapeutic Application, Company Analysis & Forecast" report has been added to ResearchAndMarkets.com\'s offering.\nUnited States Generic Drugs Market will be US$ 239.5 Billion by 2026.\nGenerics are an off-patented drug that is pharmaceutical equivalents to branded medicines in term of administrative dosage, quality, effect, intended use and side effects.
  • In the United States, generic drug production has increased because it is cheaper than any branded medicine.
  • In the United States, the decline in medicine price works as the biggest catalyst for the generic drug market growth.
  • These generic medicines prices sometimes declined to 85% less than patented drugs; this happens when various generic drug companies target a single patented drug.

Worldwide Specialty Generics Industry to 2026 - Players Include Teva Pharmaceuticals, Akorn and Mylan Among Others

Retrieved on: 
Wednesday, April 21, 2021
Pharmaceutical companies, Life sciences, Biotechnology, Pharmaceutical industry, Pharmaceuticals policy, NIFTY 50, Generic drug, Public domain, Teva Pharmaceuticals, Mylan, Specialty drugs in the United States, Endo International

b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Specialty Generics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global specialty generics market reached a value of US$ 57.3 Billion in 2020.

Key Points: 
  • b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Specialty Generics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global specialty generics market reached a value of US$ 57.3 Billion in 2020.
  • Specialty generics are generic versions of specialty drugs, once they get off-patent.
  • Looking forward, the publisher expects the global specialty generics market to exhibit strong growth during the next five years.\nThis latest report provides a deep insight into the global specialty generics market covering all its essential aspects.
  • Some of the leading players operating in the market are Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp., Endo International plc.\nKey Questions Answered in This Report:\nHow has the global specialty generics market performed so far and how will it perform in the coming years?\nWhat are the key regional markets in the global specialty generics industry?\nWhat has been the impact of COVID-19 on the global specialty generics industry?\nWhat is the breakup of the global specialty generics market based on the indication?\nWhat is the breakup of the global specialty generics market based on the route of administration?\nWhat is the breakup of the global specialty generics market based on the distribution channel?\nWhat are the various stages in the value chain of the global specialty generics industry?\nWhat are the key driving factors and challenges in the global specialty generics market?\nWhat is the structure of the global specialty generics industry and who are the key players?\nWhat is the degree of competition in the global specialty generics market?\n'

Global Generic Drugs Market Forecast & Opportunities, 2026: Increasing Count of Drug Patent Expirations is Expected to Bolster Market Growth

Retrieved on: 
Wednesday, April 21, 2021
Life sciences, Pharmaceuticals policy, Articles, Pharmaceutical industry, Biotechnology, Generic drug, Public domain, Biosimilar

b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Global Generic Drugs Market, By Type (Small Molecule Generics vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Others), By Drug Delivery, By Form, By Source, By Distribution Channel, By Company, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Generic Drugs Market was valued at USD371.04 billion in 2020 and is anticipated to reach USD564.43 billion until 2026 by witnessing a CAGR of 7.08% during the forecast period.\nThe Global Generic Drugs Market is driven by rising prevalence of chronic diseases across the globe.

Key Points: 
  • b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Global Generic Drugs Market, By Type (Small Molecule Generics vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Others), By Drug Delivery, By Form, By Source, By Distribution Channel, By Company, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Generic Drugs Market was valued at USD371.04 billion in 2020 and is anticipated to reach USD564.43 billion until 2026 by witnessing a CAGR of 7.08% during the forecast period.\nThe Global Generic Drugs Market is driven by rising prevalence of chronic diseases across the globe.
  • Moreover, availability of generic drugs at a lower cost and having the same chemical composition of branded drugs is one of the key factors which is positively impacting the growth of the market during the forecast period.
  • Also, increasing count of drug patent expirations is further expected to bolster the growth of the market over the next few years.\nThe Global Generic Drugs Market is segmented based on type, application, drug delivery, form, source, distribution channel, company, and region.
  • Other competitive strategies include mergers & acquisitions, partnership, agreements, and new developments in order to expand their geographic reach and to increase their customer base.\nTo analyze historical growth in market size of the Global Generic Drugs Market from 2016 to 2019.\nTo estimate and forecast the market size of the Global Generic Drugs Market from 2021 to 2026 and growth rate until 2026.\nTo classify and forecast the Global Generic Drugs Market based on type, application, drug delivery, form, source, distribution channel, company and regional distribution.\nTo identify dominant region or segment in the Global Generic Drugs Market.\nTo identify drivers and challenges for the Global Generic Drugs Market.\nTo examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Generic Drugs Market.\nTo conduct pricing analysis for the Global Generic Drugs Market.\nTo identify and analyze the profiles of leading players operating in the Global Generic Drugs Market.\nTo identify key sustainable strategies adopted by market players in the Global Generic Drugs Market.\nYears considered for this report:\n'

Global Specialty Generics Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, April 19, 2021
Health, Pharmaceutical, Life sciences, Pharmaceutical industry, Biotechnology, Pharmaceuticals policy, Generic drug, Public domain, Specialty drugs in the United States

b'The "Specialty Generics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global specialty generics market reached a value of US$ 57.3 Billion in 2020.

Key Points: 
  • b'The "Specialty Generics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global specialty generics market reached a value of US$ 57.3 Billion in 2020.
  • Looking forward, the publisher expects the global specialty generics market to exhibit strong growth during the next five years.\nSpecialty generics are generic versions of specialty drugs, once they get off-patent.
  • This results in lower price reduction compared to the branded drug and consequently higher margins compared to traditional generics.
  • This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the specialty generics market in any manner.\n'

Global Generic Drugs (Small Molecule Generics vs Biosimilars) Market Forecast & Opportunities, 2021-2026 by Application, Drug Delivery, Form, Source, Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021
Health, Pharmaceutical, Life sciences, Pharmaceuticals policy, Articles, Pharmaceutical industry, Biotechnology, Generic drug, Public domain, Biosimilar

b'The "Global Generic Drugs Market, By Type (Small Molecule Generics vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Others), By Drug Delivery, By Form, By Source, By Distribution Channel, By Company, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Generic Drugs Market was valued at USD371.04 billion in 2020 and is anticipated to reach USD564.43 billion until 2026 by witnessing a CAGR of 7.08% during the forecast period.\nThe Global Generic Drugs Market is driven by rising prevalence of chronic diseases across the globe.

Key Points: 
  • b'The "Global Generic Drugs Market, By Type (Small Molecule Generics vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Others), By Drug Delivery, By Form, By Source, By Distribution Channel, By Company, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe Global Generic Drugs Market was valued at USD371.04 billion in 2020 and is anticipated to reach USD564.43 billion until 2026 by witnessing a CAGR of 7.08% during the forecast period.\nThe Global Generic Drugs Market is driven by rising prevalence of chronic diseases across the globe.
  • Moreover, availability of generic drugs at a lower cost and having the same chemical composition of branded drugs is one of the key factors which is positively impacting the growth of the market during the forecast period.
  • Also, increasing count of drug patent expirations is further expected to bolster the growth of the market over the next few years.\nThe Global Generic Drugs Market is segmented based on type, application, drug delivery, form, source, distribution channel, company, and region.
  • Other competitive strategies include mergers & acquisitions, partnership, agreements, and new developments in order to expand their geographic reach and to increase their customer base.\nTo analyze historical growth in market size of the Global Generic Drugs Market from 2016 to 2019.\nTo estimate and forecast the market size of the Global Generic Drugs Market from 2021 to 2026 and growth rate until 2026.\nTo classify and forecast the Global Generic Drugs Market based on type, application, drug delivery, form, source, distribution channel, company and regional distribution.\nTo identify dominant region or segment in the Global Generic Drugs Market.\nTo identify drivers and challenges for the Global Generic Drugs Market.\nTo examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Generic Drugs Market.\nTo conduct pricing analysis for the Global Generic Drugs Market.\nTo identify and analyze the profiles of leading players operating in the Global Generic Drugs Market.\nTo identify key sustainable strategies adopted by market players in the Global Generic Drugs Market.\nYears considered for this report:\n'

Outlook on the Generic Drugs Global Market to 2026 - by Therapy Area, Drug Delivery, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 14, 2021
Health, General Health, Pharmaceuticals policy, Generic drug, Pharmaceutical industry, Public domain, Manufacturing, Articles, Economic taxonomy

b'Key Questions Answered in This Report:\nHow has the market performed so far and how will it perform in the coming years?\nWhat are the key regional markets?\nWhat has been the impact of COVID-19 on the global generic drugs market?\nWhat are the major drug delivery segments?\nWhat are the key therapy areas?\nWhat are the major distribution channels?\nWhat are the various stages in the value chain of the industry?\nWhat are the key driving factors and challenges in the industry?\nWhat is the structure of the industry and who are the key players?\nWhat is the degree of competition in the industry?\nWhat are the profit margins in the industry?\nWhat are the key requirements for setting up a manufacturing plant?\nHow are generic drugs manufactured?\nWhat are the various unit operations involved in a manufacturing plant?\nWhat is the total size of land required for setting up a manufacturing plant?\nWhat are the machinery requirements for setting up a manufacturing plant?\nWhat are the raw material requirements for setting up a manufacturing plant?\nWhat are the packaging requirements for generic drugs?\nWhat are the transportation requirements for generic drugs?\nWhat are the utility requirements for setting up a manufacturing plant?\nWhat are the manpower requirements for setting up a manufacturing plant?\nWhat are the infrastructure costs for setting up a manufacturing plant?\nWhat are the capital costs for setting up a manufacturing plant?\nWhat are the operating costs for setting up a manufacturing plant?\nWhat will be the income and expenditures for a manufacturing plant?\nWhat is the time required to break-even?\n'

Key Points: 
  • b'Key Questions Answered in This Report:\nHow has the market performed so far and how will it perform in the coming years?\nWhat are the key regional markets?\nWhat has been the impact of COVID-19 on the global generic drugs market?\nWhat are the major drug delivery segments?\nWhat are the key therapy areas?\nWhat are the major distribution channels?\nWhat are the various stages in the value chain of the industry?\nWhat are the key driving factors and challenges in the industry?\nWhat is the structure of the industry and who are the key players?\nWhat is the degree of competition in the industry?\nWhat are the profit margins in the industry?\nWhat are the key requirements for setting up a manufacturing plant?\nHow are generic drugs manufactured?\nWhat are the various unit operations involved in a manufacturing plant?\nWhat is the total size of land required for setting up a manufacturing plant?\nWhat are the machinery requirements for setting up a manufacturing plant?\nWhat are the raw material requirements for setting up a manufacturing plant?\nWhat are the packaging requirements for generic drugs?\nWhat are the transportation requirements for generic drugs?\nWhat are the utility requirements for setting up a manufacturing plant?\nWhat are the manpower requirements for setting up a manufacturing plant?\nWhat are the infrastructure costs for setting up a manufacturing plant?\nWhat are the capital costs for setting up a manufacturing plant?\nWhat are the operating costs for setting up a manufacturing plant?\nWhat will be the income and expenditures for a manufacturing plant?\nWhat is the time required to break-even?\n'

Global Para IV Insights Database: Generic Drug Litigation Updates Service

Retrieved on: 
Wednesday, April 14, 2021
Pharmaceutical industry, Pharmaceuticals policy, Generic drug, Public domain, Life sciences, Health sciences, Health care

b'DUBLIN, April 14, 2021 /PRNewswire/ -- The "Para IV Insights Database - Global Generic Drug Litigation Updates" database has been added to ResearchAndMarkets.com\'s offering.\nPara IV litigations remain the mainstay for any generic company focused on the US generics market and consequently account for a significant chunk of revenues for all the major pharma companies in India.

Key Points: 
  • b'DUBLIN, April 14, 2021 /PRNewswire/ -- The "Para IV Insights Database - Global Generic Drug Litigation Updates" database has been added to ResearchAndMarkets.com\'s offering.\nPara IV litigations remain the mainstay for any generic company focused on the US generics market and consequently account for a significant chunk of revenues for all the major pharma companies in India.
  • Para IV Winners and Losers is an analysis of major developments in the space in a particular month.\nWho can benefit from Para IV Insight?\nTime and again the database has proven to have offered significant insights into the competitive landscape of key products much ahead of the market.
  • However, it is always important to catch the target pharma company during the drug development process and before the manufacturing starts.
  • It is here where the Para IV filing and \'Other ANDA developers\' information becomes highly critical marketing intelligence.